82 completed, 16 terminated, 11 active not recruiting, 4 withdrawn. 62 Phase 2, 47 Phase 1, 22 Phase 3, 2 Early Phase 1.
Follow Pharmacyclics LLC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Recruiting | European Research Initiative on CLL | 323 | 2025-12-18 | 2026-08-19 | |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia Ibrutinib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 333 | 2024-05-30 | 2026-09-25 |
| A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Zilovertamab, Ibrutinib, Placebo - Lymphoma, Mantle-Cell, Lymphoma | Phase 3 | Withdrawn | Oncternal Therapeutics, Inc | 2023-03-01 | 2023-04-21 | |
| A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma Ibrutinib, Lenalidomide, Rituximab - Lymphoma, Mantle-Cell | Phase 2 | Completed | Janssen Research & Development, LLC | 36 | 2022-12-06 | 2025-10-07 |
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Ibrutinib, Obinutuzumab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma | Phase 2 | Active not recruiting | University of California, Davis | 40 | 2021-02-24 | 2026-04-13 |
| A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment Free Observation - CLL, SLL | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-12-22 | 2025-05-16 | ||
| Ibrutinib + Venetoclax in Untreated WM IBRUTINIB, Venetoclax - Waldenstrom Macroglobulinemia, MYD88 Gene Mutation | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 45 | 2020-07-09 | 2026-05-11 |
| A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma Ibrutinib, Rituximab, Placebo - Marginal Zone Lymphoma | Phase 3 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 23 | 2019-12-23 | 2026-07-23 |
| Ibrutinib and Rituxan for Chronic GVHD Rituximab, Ibrutinib - Graft Vs Host Disease | Phase 2 | Terminated | Northside Hospital, Inc. | 15 | 2019-12-16 | 2024-12-13 |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Ibrutinib, Lenalidomide, Dexamethasone - Refractory Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Completed | Alliance Foundation Trials, LLC. | 14 | 2019-08-29 | 2026-01-06 |
| Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Ibrutinib, Lenalidomide, Rituximab - Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2019-01-22 | 2026-01-29 |
| Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Ibrutinib - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 59 | 2018-11-19 | 2025-10-21 |
| Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab - Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | University of California, San Diego | 5 | 2018-10-17 | 2026-05-22 |
| Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) Ibrutinib - Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2018-05-23 | 2025-09-02 |
| Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib Venetoclax, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Michael Choi | 24 | 2018-05-01 | 2024-07-05 |
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Ibrutinib, Venetoclax, Chlorambucil - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 211 | 2018-04-17 | 2026-09-28 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Oncternal Therapeutics, Inc | 95 | 2018-01-03 | 2025-02-12 |
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Ibrutinib, Lenalidomide - Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome | Phase 1 | Completed | University of California, Davis | 4 | 2017-12-01 | 2026-03-10 |
| Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg - Breast Neoplasms, Malignant Neoplasm of Breast | Phase 1 / Phase 2 | Active not recruiting | US Oncology Research | 34 | 2017-11-29 | 2024-12-06 |
Showing 20 of 115. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (31) · Lymphoma (19) · Lymphoma, Mantle-Cell (16) · Lymphoma, Follicular (15) · Lymphoma, Non-Hodgkin (14) · Leukemia (10) · Lymphoma, B-Cell (10) · Recurrence (10) · Lung Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (8) · Lymphoma, Large B-Cell, Diffuse (8) · Bronchiolitis Obliterans Syndrome (7) · Lymphoma, B-Cell, Marginal Zone (7) · Multiple Myeloma (7) · Neoplasms (7)
ibrutinib (84) · Rituximab (19) · motexafin gadolinium (17) · venetoclax (8) · obinutuzumab (7) · Lenalidomide (6) · Dexamethasone (5) · abexinostat (5) · Bendamustine Hydrochloride (4) · Vincristine (4) · Chlorambucil (3) · Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Cetuximab (2)
United States (106) · Spain (25) · United Kingdom (24) · Canada (23) · Belgium (22) · France (22) · Poland (20) · Australia (19) · Germany (19) · Russia (16) · Czechia (15) · Italy (14) · Turkey (Türkiye) (14) · Israel (12) · South Korea (12)
Brian Jonas (3) · Michael Choi, MD (3) · Thorsten Graef, MD (3) · Ariela Noy, MD (2) · Christian Grommes, MD (2) · Jan A. Burger, MD (2) · Jutta K. Neuenburg, MD, PhD (2) · Lori Styles, MD (2) · Samir Undevia, MD (2) · Ajai Chari, MD (1) · Alex Young (1) · Alvina Chu, MD (1) · Andrew Evens, D.O. (1)
PMID 31196847, PMID 28751558, PMID 40266025, PMID 25381051, PMID 25724156, PMID 26182309, PMID 23886836, PMID 26193343, PMID 26813675, PMID 29437592, PMID 29470582, PMID 29880603, PMID 32209572, PMID 34865212, PMID 35014928, PMID 35377947, PMID 36617990, PMID 37315225, PMID 40674744, PMID 16731764, PMID 17401015, PMID 18406884, PMID 23045577, PMID 23782157, PMID 23782158, PMID 24332241, PMID 24881631, PMID 25042202, PMID 25150798, PMID 25355819, PMID 25755291, PMID 26059948, PMID 26116658, PMID 26297574, PMID 26588924, PMID 26639149, PMID 26655421, PMID 26673811, PMID 27637985, PMID 28138560, PMID 28167659, PMID 28373262, PMID 28924018, PMID 29669753, PMID 29851546, PMID 30044692, PMID 30522969, PMID 30546948, PMID 30567753, PMID 30842083
2016 (3), 2017 (3), 2023 (3), P30CA093373 (3), 2015 (1), R01CA190628 (1)